This shift in vaginal pH from acidic (low pH) toward alkaline (higher pH) favors colonization by pathological urinary and vaginal bacteria (commonly E. coli from stool), which increases susceptibility to both vaginal infections and ascending UTIs. This mechanism is central to the genitourinary syndrome of menopause (GSM).<\/p>\n
Restoring healthy vaginal pH using vaginal estradiol<\/strong>\u00a0can dramatically cut rates of both urinary and vaginal infections, and reduce the risk of serious complications, such as kidney infections and even more serious sepsis. Local topical vaginal estradiol therapy is an evidence-based therapy for restoring the acidic environment, promoting lactobacilli, and substantially reducing recurrent UTI rates, often by 50% or more in studies<\/strong><\/em>.<\/p>\n Vaginal estradiol (which can be in the form of a generic Rx cream, vaginal ring, or vaginal tablet) is a common sense, low cost, non-antibiotic prophylaxis approach that will not only reduce UTIs but also help prevent sepsis and help keep women out of the hospital.<\/strong><\/p>\n Tragically for women, many clinicians are either unaware of this estrogen connection in UTIs or they refuse to consider vaginal estradiol Rx due to erroneous beliefs held over from the earlier, misleading FDA black box warnings the makers of Premarin and Prempro lobbied to have applied to all <\/em>estrogen products after their products were implicated in the 2001 Women\u2019s Health Initiative risks.\u00a0 This black box warning never should have applied to all estrogen products, especially low dose vaginal estrogen. Women have suffered for the last 25 years from being denied proper estrogen therapy.\u00a0 The Trump Administration FDA Commissioner in 2025 finally removed this black box warning from the FDA required labeling, <\/em>but many doctors, nurse practitioners, and PAs treating women still do not know that.<\/p>\n There is further good news.\u00a0 After 25 years of misinformation, under the leadership of HHS Secretary RFK, Jr and new FDA and NIH leadership, there have been major efforts made to undo the damage from the flawed reports from the WHI. Medicine in the U.S. is finally, slowly catching up to what has been known since the 1980s and studies I included in my 1995 book Screaming to be Heard \u2013 Hormone Connections Women Suspect and Doctors Ignore <\/em><\/strong>(2001 revised and updated edition available on Amazon in hardback and Kindle).<\/p>\n The American Urology Association (AUA) also finally in 2025 updated their guidelines from the last publication in 2019 to now say that women in perimenopause and postmenopausal who struggle with recurrent UTIs should be given vaginal estradiol to reduce the risk of further urinary tract infections.<\/p>\n Why estrogen matters to decrease UTI risk<\/strong><\/p>\n In women\u2019s reproductive years, estrogen\u2014primarily the active form of 17-beta estradiol (E2)<\/em>\u2014quietly maintains a powerful defense system in the vagina and lower urinary tract. Estrone (E1) is the \u201creservoir\u201d form of estrogen mainly in body fat, while estriol (E3) is a placental estrogen during pregnancy, but isn\u2019t as potent to maintain vaginal tissue health.<\/p>\n Estradiol has several key functions to maintain urogenital health:<\/strong><\/p>\n When estrogen falls\u2014as it does with onset of menses each month, after delivery of a baby, after surgical menopause, in natural perimenopause and post menopause, or with certain hormone\u2011lowering therapies\u2014these normal vaginal and urinary defenses are seriously weakened: vaginal lining gets thinner, drier, more fragile and prone to tears, pH rises, lactobacilli die off,\u00a0 and more aggressive, infection-causing bacteria now have a favorable environment to grow.\u00a0 In a nutshell, this is the reason UTIs occur more frequently in women whose vaginal estrogen levels are low.<\/p>\n Younger women on high progestin (or progestin-only) contraceptives also have suppressed overall estrogen and lower vaginal estrogen, making them also more susceptible to UTIs and more serious infections for all the reasons I outlined above.<\/p>\n How common are UTIs and why this matters<\/strong><\/p>\n UTIs are the most common bacterial infection in women. About\u00a050\u201360% of women will experience at least one UTI in their lifetime<\/strong>, and roughly a quarter of those will have recurrent infections.\u00a0 Recurrent UTI is typically defined as\u00a0two infections in six months or three in a year<\/strong>. The number of women with recurrent UTIs are rising in those who have gotten the COVID injections because the spike protein and LNPs in the mRNA shots damage ovarian hormone production and also interfere with normal immune system regulation.<\/p>\n Beyond discomfort, recurrent UTIs can create a cascade of problems:<\/strong><\/p>\n BOTTOM LINE: <\/strong>UTIs are not always \u201csimple.\u201d For women with underlying risk factors, reducing the number and severity of urinary infections can become a matter of life and death\u2014not just treating a nuisance problem.<\/strong><\/p>\n Genitourinary Syndrome of Menopause: Another Related and Common Problem<\/strong><\/p>\n As women enter perimenopause and menopause, estradiol levels drop, and a cluster of symptoms called\u00a0genitourinary syndrome of menopause (GSM)<\/strong>\u00a0increases dramatically, becoming a significant problem for up to 84% of postmenopausal women.<\/p>\n Symptoms include vaginal dryness, burning, itching, pain with intercourse, urinary urgency and frequency<\/em><\/strong>.<\/p>\n These medical problems are not just \u201cannoying,\u201d as women are often told. These physiological changes after loss of estradiol directly increase UTI risk, and in turn increase risk of more serious infections:<\/p>\n Clinical studies show that postmenopausal women are\u00a0disproportionately affected by recurrent and complicated UTIs<\/strong>, compared with younger women. So, when you add comorbidities like diabetes, chronic kidney disease, or heart failure, the likelihood that a UTI will escalate into full-blown sepsis increases even further.\u00a0 Genitourinary Syndrome of Menopause is not just about comfort<\/em>; it\u2019s a\u00a0risk state for recurrent infection and more serious systemic infections<\/strong>.<\/p>\n Vaginal estradiol: the many ways it reduces risk of infections<\/strong><\/p>\n Vaginal estradiol delivers a small dose of estrogen directly to the vaginal tissues, with minimal systemic absorption, especially at low doses. The goal is not to \u201craise hormones everywhere,\u201d but to\u00a0repair and restore the health of the local tissues in the vagina.\u00a0 Vaginal estradiol works to:<\/strong><\/p>\n Clinical data supports these effects of vaginal estradiol:<\/strong>:<\/p>\n BOTTOM LINE:<\/strong> Vaginal estradiol used regularly leads to fewer UTIs which means fewer antibiotics, fewer kidney infections, and a lower chance of sepsis in high\u2011risk women.<\/strong><\/p>\n Review of Current AUA Guidelines:\u00a0 <\/strong>Major urology societies have updated their guidance for women based on this overwhelming evidence:<\/p>\n The\u00a0AUA\/SUFU\/AUGS Genitourinary Syndrome of Menopause Guideline (2025)<\/strong>\u00a0<\/a>states that for women with GSM and recurrent UTIs, clinicians\u00a0should recommend low\u2011dose vaginal estrogen<\/strong>\u00a0to reduce future infections, assuming no contraindications and using shared decision\u2011making.\u00a0 The updated guideline lists vaginal estrogen as a\u00a0non\u2011antibiotic preventive strategy<\/strong>\u00a0for peri\u2011 and postmenopausal women, along with options like cranberry and methenamine.<\/p>\n These recommendations refer broadly to\u00a0\u201clocal low\u2011dose vaginal estrogen\u201d<\/strong>\u2014in the United States in practice, the most common and most reliable forms of estrogen are the commercially-available, prescription\u00a0FDA\u2011approved estradiol vaginal tablets (Vagifem and generics), vaginal ring (Estring), or low\u2011dose estradiol creams (Estrace brand and several generics)<\/strong>, which have robust safety and absorption data.<\/p>\n NOTE on COST AND AVAILABILITY: <\/strong>These vaginal estradiol products I listed above are available in the US at low cost in local pharmacies, and are typically covered by medical insurance plans.\u00a0 These estradiol products are also available with your physician\u2019s Rx through TheHRTClub.com<\/strong> at steep discounted cash pay direct to consumer prices.<\/p>\n You do not need the more expensive compounded products advertised by \u201chormone doctors\u201d and compounding pharmacies (who like to sell their own formulas because they have much higher markups and profits than possible with FDA-approved commercially available E2 options. <\/em><\/p>\n BOTTOM LINE: <\/strong>This is an important shift: major specialty societies now consider vaginal estrogen\u00a0standard of care<\/u>\u00a0for recurrent UTI prevention in women with low estrogen.\u00a0 It should be your first step, not a last\u2011ditch approach!<\/strong><\/p>\n Try our GSM and UTI Assessment Tool! <\/strong><\/p>\n Click here to access our patient education self-test tool<\/a> <\/strong>from Truth for Health Foundation<\/a><\/strong>\u00a0\u2014 developed by Elizabeth Lee Vliet, M.D. and Kathy Kresnik to assist you with self-screening that\u00a0helps identify signs consistent with Genitourinary Syndrome of Menopause (GSM).\u00a0 Our tool follows the criteria defined by the AUA\/SUFU\/AUGS as symptoms and tissue changes from declining estrogen and androgen in the genitourinary tract during the menopause transition.\u00a0 Our tool helps identify your risk factors for recurrent urinary tract infections (UTIs) and helps you start a constructive conversation with your health care professional about use of vaginal estrogen to alleviate symptoms and reduce risk of infections.<\/p>\n This report references the 2025 AUA\/SUFU\/AUGS Guideline on Genitourinary Syndrome of Menopause<\/a>\u00a0(J Urol. 2025;214(3):242-250) and the 2025 AUA\/CUA\/SUFU update on Recurrent Uncomplicated UTIs in Women<\/a>\u00a0(J Urol. 2026;215(1):3-12). Recurrent UTI is defined as \u22652 episodes in 6 months or \u22653 episodes in 12 months. Both guidelines emphasize shared decision-making \u2014 treatment choice should reflect your goals, preferences, and risk profile, discussed with a licensed clinician.<\/p>\n This tool is provided by Truth for Health Foundation<\/a>, a 501(c)(3) public charity as an educational service to help you talk with your personal physician(s).\u00a0 It is not medical advice.\u00a0 Our tool is a screening aid, not a diagnostic device. It does not prescribe medication and does not replace an in-person evaluation, pelvic exam, or urinalysis\/culture where clinically indicated.<\/p>\n Who should consider vaginal estradiol? <\/strong><\/p>\n Over the 40 years of my medical practice specializing on the overlooked hormone connections from puberty to late life in women and men, I have used combinations of vaginal estradiol with systemic hormone treatment for the whole range symptoms women experience as a result of hormone imbalances, whatever the cause.\u00a0 I have found that systemic hormone therapy alone doesn\u2019t always prevent vaginal and urinary symptoms \u2013 we need the topical effects locally on the vaginal and urinary tissues. I describe my approaches in more detail in my books, especially Screaming to be Heard \u2013 Hormone Connections Women Suspect and Doctors Ignore <\/em><\/strong>(2001 revised and updated edition available on Amazon in hardback and Kindle), especially the chapter on Estrogen and the Bladder.<\/p>\n I don\u2019t see vaginal and urinary symptoms as something to only be treated with topical estrogen if BOTH are present, as the AUA 2025 guideline suggests.\u00a0 Either problem alone responds to local estradiol therapy, if done consistently at the right dose, with the right product for each woman, and for the right duration of time.\u00a0 Some women use vaginal estradiol options for years, with excellent results to prevent UTIs, urinary leakage, and pain with intercourse due to dryness.\u00a0 So with this background in mind based on my many years of actual clinical experience treating thousands of women, let\u2019s look at what the guidelines say (clearly, more rigid than what I actually do in practice to help individual patients based on their needs).<\/p>\n Safety: what the data actually show<\/strong><\/p>\n It is a national tragedy that more doctors are still operating in fear about \u201cestrogen\u201d from the flawed WHI study that hit the news in 2002, with exaggerated headlines about risk (since disproven) and ignored benefits. This problem requires more background than I can go into in this short Health Tip.\u00a0 So I am focused here solely on safety data using the low\u2011dose vaginal estradiol options.<\/p>\n This doesn\u2019t mean \u201cno risk\u201d in every case, and women need individualized assessments and discussion of risks.\u00a0 But overall, the\u00a0risk profile of vaginal estradiol is minimal <\/strong>and in many women, the\u00a0benefits clearly outweigh the risks<\/strong>.<\/p>\n What this means for doctors\u2014and for women<\/strong><\/p>\n For decades, the reflex UTI strategy has been \u201ctreat with antibiotics, repeat as needed.\u201d That approach ignores the root cause of low estradiol in millions of women with genital and urinary tissues. The newer evidence and guidelines tell a different story: vaginal estradiol is a core component of effective prevention and treatment. To our readers, if your doctor has closed the book on hormone therapy because of a 24-year old flawed study and has not read anything on it since 2002, it is time to look for a new doctor!<\/p>\n In summary, we know (and have known for several decades) that vaginal estradiol\u00a0cuts UTI rates by half or more<\/strong>\u00a0in women with low estrogen and recurrent infections. It addresses the\u00a0underlying vulnerability<\/strong>\u2014thin tissue, disrupted microbiome, weak local immunity\u2014rather than just killing bacteria after they\u2019ve already invaded. It can reduce antibiotic exposure, resistance, and the risk of dangerous complications like pyelonephritis and urosepsis, especially in older or comorbid women.<\/p>\n Given all that I have shared with you in this Health Tip, it is time for doctors to:<\/strong><\/p>\n BOTTOM LINE: For women, the practical message is straightforward:<\/strong> How Do I Restore the Vaginal and Gut Microbiome After Antibiotics for UTIs? <\/strong><\/p>\n There are several ways to restore the healthy bacterial balance in the vagina, and for the gut as well if you had to take a systemic antibiotic to treat a UTI. First of all, I encourage you to read my earlier Health Tips on the unique features of our high-quality multi-species, multi-strain probiotics, available here:\u00a0 https:\/\/www.truthforhealth.org\/2024\/04\/health-tip-from-dr-vliet-featuring-truprobiotic-complex\/<\/a> After a course of systemic antibiotics, you really should consider taking a two week course of a high volume, multi-strain probiotic.\u00a0 Then change to a daily probiotic with a variety of foods that are fermented and provide prebiotic fiber.\u00a0 These steps will help tremendously. For myself, my family and my patients, I recommend the TruProbiotic Complex <\/strong>followed by the TruProbiotic Daily<\/strong> to replenish bifidobacteria and other needed species.<\/p>\n You may also want to consider the synergistic benefit with a vaginal probiotic option to further support vaginal microbial balance.\u00a0<\/strong><\/p>\n One tool I recommend to patients navigating this is V-Probiotics by Vitanica<\/a>,<\/strong> a vaginal suppository containing five targeted Lactobacillus strains (including L. crispatus, L. gasseri, and L. jensenii, L. reuteri, and L. rhamnosus) that are naturally dominant in a healthy vaginal microbiome.<\/p>\n Research shows that women whose vaginal flora is rich in these specific species have lower rates of vaginal dryness, atrophy, and irritation (Journals of Gerontology<\/a>), and multiple clinical trials have found that restoring vaginal Lactobacillus \u2014 particularly L. crispatus \u2014 meaningfully reduces recurrent UTI episodes in women prone to them, including postmenopausal women (Clinical Infectious Diseases<\/a>; Frontiers in Microbiology<\/a>).<\/p>\n This new product we added to our Truth for Health Store is specifically formulated to help restore the protective vaginal balance that reduces risk of another vaginal bacterial infection or UTI.<\/p>\n V-Probiotics<\/strong> <\/a>is a new product we have added to our store! As you put all the pieces together that I have described today, I encourage you to consider our other natural medicines with our top quality, cGMP-compliant professional formulas: TruMitochondrial\u2122 Boost,\u00a0 TruNAC\u2122, Tru BioD3, Tru B\u2122 Complex Full Spectrum, TruZinc\u2122, TruC with BioFlavonoids\u00a0 <\/em>(Natural sourced Vitamin C with complete Bioflavonoids), and TruProBiotic\u2122 Daily <\/em><\/strong>to replenish critical bifidobacteria depleted by COVID shots, viral illnesses, and antibiotic therapy.<\/p>\n All Truth for Health Foundation Products Meet or Exceed cGMP Quality Standards, the highest quality standard for supplements sold in the USA. For more information, references from studies are listed in the Product Data Sheets for each product, available on our website.<\/em><\/strong>\u00a0 Check us out at www.TruthforHealth.org<\/a> Click on tab for Store.\u00a0 OR www.shopTruthforHealth.com<\/a><\/p>\n\n
<\/p>\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\nIf you\u2019re having multiple UTIs a year, and you\u2019re also noticing vaginal dryness, pain with sex, or urinary urgency, there is a good chance that low local estrogen is part of the problem. Ask your clinician specifically about\u00a0low\u2011dose vaginal estradiol for prevention<\/strong>, not just \u201cmore antibiotics.\u201d Bring up the newer urology guidelines and your infection history. You\u2019re not being difficult\u2014you\u2019re advocating for a solution that treats the root cause!\u00a0 Don\u2019t be passive and silent when it comes to your health!<\/strong><\/p>\n
\nhttps:\/\/www.truthforhealth.org\/2024\/03\/health-tip-from-dr-vliet\/<\/a><\/p>\n<\/a>Combining vaginal estradiol with a Lactobacillus-based vaginal probiotic like V-Probiotics targets two complementary mechanisms of genitourinary syndrome of menopause (GSM) and recurrent UTI risk, and the evidence supports real synergy.\u00a0 Vaginal estradiol restores glycogen in the vaginal epithelium, which is the fuel Lactobacillus needs to recolonize and produce protective lactic acid. Multiple studies confirm topical vaginal estrogen reliably increases Lactobacillus abundance, lowers vaginal pH, and restores a healthier microbiome community \u2014 effects that are most pronounced in women who start out with a dysbiotic (Lactobacillus-poor) vaginal microbiome.\u00a0 Then adding a direct probiotic supplies the beneficial bacteria themselves rather than waiting for estrogen alone to recruit them, which can accelerate and reinforce recolonization.<\/p>\n
\nWhile there isn’t a clinical trial on this exact commercial blend, the strains it contains are well-studied and have an excellent safety record, with no serious side effects reported across the research. It’s a gentle, low-risk option that works well on its own or alongside vaginal estrogen for women looking for extra support with dryness, discomfort, or recurrent UTIs during this life stage. As always, check with your own personal health professional before starting any new supplement, especially if you’re pregnant or have a specific vaginal health concern that needs evaluation first.<\/p>\n